title: Successful treatment of refractory duodenal Crohn's disease with infliximab.
authors.affiliation: Department of Gastroenterology, Akita University of Medicine, 1-1-1, Hondo, Akita city, Akita 010-8543, Japan. odashima@doc.med.akita-u.ac.jp
authors.forename: Masaru
authors.initials: M
authors.lastname: Odashima
authors.forename: Michiro
authors.initials: M
authors.lastname: Otaka
authors.forename: Mario
authors.initials: M
authors.lastname: Jin
authors.forename: Youhei
authors.initials: Y
authors.lastname: Horikawa
authors.forename: Tamostu
authors.initials: T
authors.lastname: Matsuhashi
authors.forename: Reina
authors.initials: R
authors.lastname: Ohba
authors.forename: Shigeto
authors.initials: S
authors.lastname: Koizumi
authors.forename: Nobukatsu
authors.initials: N
authors.lastname: Kinoshita
authors.forename: Taiji
authors.initials: T
authors.lastname: Takahashi
authors.forename: Sumio
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003092:Colitis / Q000188:drug therapy*; D003251:Constriction, Pathologic; D003424:Crohn Disease / Q000188:drug therapy*; D004386:Duodenum / Q000473:pathology*; D016099:Endoscopy, Gastrointestinal; D006801:Humans; D000069285:Infliximab; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab